Get Started

PYXS

NASD Pyxis Oncology, Inc.
Oct 23, 2026 · 12:25 PM ET DELAYED Market Open

$1.70 ↓ -0.01 (-0.58%) Trading Down from the previous close of $1.71, $0.01 below the day’s high of $1.71

YTD change
+47.83%
vs 20-day SMA
-18.68%
vs 200-day SMA
-21.16%

Price ranges

Previous day
$1.70 $1.79
open $1.74 close $1.71
-$0.03 (-1.72%)
Today
$1.63 $1.71
open $1.70 now $1.70
+$0.00 (+0.00%)
Past week
$1.66 $1.90
from $1.80 now $1.70
-$0.10 (-5.56%)
Past month
$1.66 $2.94
from $2.92 now $1.70
-$1.22 (-41.78%)
This year
$1.13 $4.15
from $1.15 now $1.70
+$0.55 (+47.83%)

Price & Performance

+0.00 (+0.00%) / 6M

$1.45$2.32$3.20$4.07Apr 23Jul 24Oct 22

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 91.1% away from all-time highs of $19.00
  • PYXS is up 48% since the beginning of the year
  • PYXS is down 50% over the past 12 months
  • PYXS is down 42% over the past 1 month
  • 5% of all PYXS investors are betting against PYXS

PYXS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -49.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.4
Earnings momentum -43.8% Quarterly EPS growth
Quarterly change -43.8%

Valuation

P/E ratio N/A
Enterprise value $92.8M
Beta 1.26

Balance sheet & scale

IncomeN/A
Revenue$11.0M
Cash$34.5M
Debt$17.8K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $206.3M

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $447.28 +2.04%
MRNA Moderna, Inc. $202.63 -17.57%
RVMD Revolution Medicines, Inc. $187.69 -3.39%
ROIV Roivant Sciences Ltd. $37.45 +1.77%
BNTX BioNTech SE Sponsored ADR $89.67 -1.77%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.